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Abstract
Background: Up to the point of writing this review, there is no scientific evidence of any
effective medical therapy for coronavirus disease 2019 (COVID-19). In this review, we
attempted to discuss the current summary of evidence of some medication, currently
in trial for the treatment of COVID-19.
Material and Methods: We have done an electronic literature search using the
following database: PubMed, Medline, Scopus and Google scholar. These databases
were searched using the keywords COVID-19 and pharmacological therapy.
Results: At present, there are no well randomized controlled studies which can give
evidence for most of the therapy used for COVID-19. Several medications are in
trials for COVID-19, among them: 1/ chloroquine and hydroxychloroquine; 2/anti-virals
oseltamivir, remdesivir, lopinavir/ritonavir and other protease inhibitors; 3/antibiotics
macrolide (Azithromycin); 4/cytokine therapy interferon; 5/ humanized monoclonal
antibody tocilizumab; 6/adjunct therapies vitamins C, D, and herbal medicine; 7/
COVID-19 convalescent plasma; 8/systemic steroids; 9/expected COVID-19 vaccine.
We have also included some of the herbal medicines that are commonly and widely
used in the Middle East, Asia as well in Sudan, (black seeds, honey and Acacia Nilotica).
It is worth mentioning that these herbal medicines have shown benefits in treating other
diseases, but the evidence of their benefit in COVID-19 still needs to be established.
Conclusion: Currently there is no pharmacological therapy for the COVID-19. More
research and randomized clinical trials are needed to find effective therapy or vaccine
against COVID-19.
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1. Introduction
Since the declaration of COVID-19 as a pandemic in January 2020, the number of cases
of infection and mortality continued to rise steadily, as have mortality rates [1–4]. The
search for a treatment or vaccine is the main challenge for all scientists across the
globe who work in this field. In this short review, we attempted to discuss some of the
pharmacological therapies used or have potential benefit in COVID-19.
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2. Material and Methods
We have performed an electronic literature search using the following database: pub
Med, Medline, Scopus and Google scholar. These databases were searched using the
keywords COVID-19 and pharmacological therapy. The authors searched also using a
combination of the following terms [(COVID-19) AND (therapy) AND (treatment)] OR the
name of different medication with COVID19]. The search based on studies published in
the English language without restriction for the publication date. However, most of the
published materials were found to be published in 2020.
3. Results and Discussion
3.1. Chloroquine and hydroxychloroquine
Chloroquine and hydroxychloroquine were shown to inhibit the replication of COVID-19
cells in vitro through increasing pH of lysosomes [1, 2] and other intracellular acidic
organelles and preventing fusion of the virus to the host cell [4–7]. Also, chloroquine
and hydroxychloroquine have an immunomodulatory effect that theoretically could
contribute to an anti-inflammatory response in patients with viral infections. These
agents were synthesized for the treatment of malaria and have been used for the
treatment of other illnesses such as systemic lupus erythematosus and other rheumatic
conditions [3]. They are generally well tolerated with commonly reported adverse effects
like nausea, vomiting, itching and headache. Other serious adverse effects include
QTc prolongation, hematologic toxicities, and hypoglycemia. These side effects are
uncommon but require appropriate monitoring and patient selection [4]. Hydroxychloro-
quine and chloroquine can have significant drug interactions, especially with drugs with
potential for QTc prolongation. Due to uncertainty in benefits and harms, infectious
diseases society of America (IDSA) guidelines on the treatment and management of
patients with COVID-19 recommends the use of hydroxychloroquine in the context of
the clinical trial [5, 8]. The guideline on the management of critically ill adults with COVID-
19 by the Surviving Sepsis Campaign (SSC) and the National Institute of Health (NIH)
did not make a recommendation for or against its use, however, NIH recommended
against the use of high dose hydroxychloroquine [6, 11].
3.2. Azithromycin
Azithromycin (C38H72N2O12) is a macrolide antibiotic that acts by inhibiting protein
synthesis through binding to 50S ribosomal subunit [9]. Macrolides are some of the most
commonly prescribed antibiotics. They are used for a wide range of acute and chronic
infections. Adverse events profile includes gastrointestinal symptoms, taste disturbance
and hearing loss [10]. Azithromycin has been studied for the treatment of COVID-19
in combination with hydroxychloroquine. Although azithromycin itself is not usually
associated with QTc prolongation, its use with hydroxychloroquine may increase the
risk of torsades de pointes. Due to safety concerns and limited poor-quality evidence,
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Infectious diseases society of America (IDSA) and National Institutes of Health (NIH)
recommend the use of hydroxychloroquine and azithromycin combination to be limited
to clinical trials [5, 11].
3.2.1. Remdesivir
Remdesivir (C27H35N6O8P) is an investigational broad-spectrum antiviral [5]. It causes
premature termination of RNA transcription after conversion to an adenosine analogue.
Although remdesivir is considered the most promising drug, IDSA, and SSC did not
make recommendations regarding its use due to insufficient evidence. More recently,
NIH recommended the use of remdesivir for patients hospitalized for severe COVID-19.
It also recommended that its use for mild to moderate disease be limited to the setting
of clinical trials [11]. It can cause gastrointestinal side effects, elevated liver enzymes and
elevated prothrombin time [5, 6, 12]. First randomized, double-blind, placebo-controlled,
multicenter trial of use remdesivir in adults with severe COVID-19 published in lancet last
April 2020 included 237 patients were enrolled (158 to remdesivir and 79 to placebo).
This study concluded that remdesivir use was not associated with a difference in time
to clinical improvement (95% CI 0·87–1·75) which is not statistically significant, however,
patients receiving remdesivir had fast clinical improvement with symptom duration of
10 days or less [12].
3.2.2. Oseltamivir
Oseltamivir (C16H28N2O4) is an antiviral drug used for treatment and prophylaxis
of influenza A and B. It exerts its action by inhibiting neuraminidases enzyme and
preventing the release of the virus from the host cell [11]. Neuraminidases is not known to
be found in SARS-CoV-2, thereby the mechanism is unclear. There the use of oseltamivir
was already reported during the COVID-19 epidemic in China, either with or without
antibiotics and corticosteroids [14], however, some trials studying oseltamivir as a part
of a combination with chloroquine and favipiravir are underway [15].
3.2.3. Lopinavir/ritonavir and other protease inhibitors
Lopinavir (C37H48N4O5) is an antiretroviral drug used in combination with the pharma-
cokinetic enhancer ritonavir for the treatment of human immunodeficiency virus (HIV)
[10]. Lopinavir inhibits 3-chymotrypsin-like protease of SARS-CoV-2 in vitro. Gastrointesti-
nal adverse effects are commonly observed, in addition to possible QTc prolongation
and elevated transaminases [11]. The Surviving Sepsis Campaign (SSC) guideline sug-
gests against the use of lopinavir/ritonavir for treatment of COVID-19 in critically ill adults,
while IDSA and NIH recommend limiting to clinical trials [5, 6, 13]. These recommenda-
tions are derived from the results of a small randomized controlled trial which failed to
show the benefit of this intervention [13]. NIH also recommends limiting the use of other
protease inhibitors to clinical trials, however SSC makes no recommendation on their
use due to insufficient evidence [6, 10]. Several trials involve lopinavir-ritonavir treatment
DOI 10.18502/sjms.v15i5.7014 Page 48
Sudan Journal of Medical Sciences Baha Eldin Hassan Juma et al
in comparison with the use of other drugs for COVID-19 are going on, however the
combination of lopinavir-ritonavir was associated with clinical improvement comparing
with standard care procedures [13].
3.3. Interferons
Used for their antiviral activity, interferons are a group of cytokines that are being
considered as a potential therapy for COVID-19. Many interferons have in vitro effect
against SARS-CoV and MERS-CoV. They are usually used for the treatment of viral
hepatitis and some types of malignancies. For the treatment of COVID-19, they are
used in combination with ribavirin or lopinavir/ritonavir. Flu-like symptoms, hematologic
toxicity and depression are amongst the most common adverse effects of interferons.
The NIH recommends limiting the use of interferons to clinical trials while Surviving
Sepsis Campaign was not able to issue a recommendation due to insufficient evidence
[6, 10]. During the writing of this review, in Hong kong, a multicenter, prospective, open-
label, randomized, phase 2 trial was conducted using Triple combination of interferon
beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of adult COVID 19 patients.
More clinical trials are needed to evaluate the efficacy and safety of recombinant human
interferon in treating patients with new coronavirus infection.
3.3.1. Tocilizumab
Tocilizumab is a humanized monoclonal antibody that inhibits interleukin-6. It is
expected to suppress the possible high immune response in COVID-19 patients. It
is used for the treatment of conditions like cytokine release syndrome and rheumatoid
arthritis, but it is associated with an increased risk of infections [6]. NIH and SCC made
no recommendation regarding the use of tocilizumab because of insufficient data, while
IDSA recommends limiting its use to clinical trials settings [5, 6, 11]. Adequately powered
randomized controlled trials are in need to determine the efficacy of tocilizumab with
consideration of the toxicity of this medicine.
3.3.2. COVID-19 Convalescent Plasma
This is theoretically done by taking plasma which contains neutral antibodies from those
who recovered from COVID-19 and transfused to patients with COVID-19. The rationale
behind this therapy it could provide short-term passive immunity against COVID-19,
decrease viral load and improves the outcome [17]. As reported at SARS pan epidemic
2003 use of convalescent plasma obtained from patients provide some benefits (shorter
duration of hospitalization, decreased mortality). Moreover, those who received the
plasma within less than 14 days from the start of symptoms have a better outcome [18].
Efficacy data are not available from controlled clinical studies to date. Multiple registered
clinical trials initiated in the US and other countries to evaluate the use of COVID-19
convalescent plasma. IDSA and NIH did not make recommendations regarding the
use of convalescent plasma outside of the clinical trial setting, however, SCC suggests
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against its routine use in critically ill adults. This recommendation is driven by previous
studies for other viral infections like Ebola and influenza which showed no benefit. In
addition to uncertainty regarding its preparation [5, 6, 11].
3.3.3. Systemic Corticosteroids
The rationale of the use of systemic steroids to maintain a systemic anti-inflammatory
that will minimize the symptoms of COVID-19 especially on those patients complicated
with severe respiratory sequences (ARDS). However, WHO does not recommend the
liberal use of systemic steroids unless patients are recruited in clinical studies or
there is another medical indication [19]. Importantly, the use of steroid during the
MERS epidemic was associated with increase in use of invasive ventilation and raised
mortality rate at 90 days [20]. NIH (strong recommendation) and IDSA (conditional
recommendation) do not support the routine use of corticosteroid. On the other hand,
SCC (weak recommendation) and NIH (moderate recommendation) support the use
of low dose corticosteroid in COVID-19 patients in refractory shock. For patients on
mechanical ventilation without acute respiratory distress syndrome (ARDS), SCC (weak
recommendation) and NIH (strong recommendation) do not recommend the use of
corticosteroids, however, SCC suggests using corticosteroids for patients with ARDS
[5, 6, 11].
3.3.4. Vitamins C and D
The use of vitamins C and D was associated with many benefits in term of increasing
the effectiveness of the immune system and increase wound healing with vitamin C.
Interestingly, vitamin C infusion was associated with improvement in the prognosis
of severe acute respiratory tract infections in COVID-19 patients and this could be
attributed to the improvement of alveolar epithelization in severe respiratory distress
syndrome patients [21, 22]. Furthermore, vitamin D has a role in mitigating the scope of
acquired immunity and endothelial lining regeneration, hence this may minimize alveolar
damage caused in ARDS. Vitamin D supplementation has a 12% overall protective effect
against bacterial and viral acute respiratory tract infection [23]. Indeed, there is no harm
from using these vitamins during the COVID-19.
3.3.5. Vaccine
There is currently no vaccine available to protect against COVID-19. Multiple registered
clinical trials are ongoing worldwide in Europe and USA as well as Asia. One of the
leading candidates is the mRNA-1273 vaccine which was developed by the National
Institute of Allergy and Infectious Diseases (NIAID) scientists. This vaccine is currently in
Phase I trial. The estimated completion time is June 2021 [24]. Once a safe and effective
vaccine becomes available it will be vital that it is accessible to everyone who needs it
(WHO reports).
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TABLE 1: Summary of current data on selected COVID-19 therapies.
Drug Preclinical data Safety
considerations
Recommendations (outside the
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3.3.6. Traditional and herbal medicine
Many reports and news from cultural and religious background reported some herbal
traditional medicine have been used with no scientific background or pharmacological
evidence. Reports from china that Chinese herbal formula might be associated with
blocking of the proliferation and replication of the virus particles, therefore, can minimize
viral load sequences.
Natural honey was also widely used during COVID-19 in these countries, either alone
or in combination with Nigellla sativa. Certain herbs, if misused, could boost the immune
system even more and lead to “a cytokine storm,” or a fatal overactive immune response,
according to Gersh [25]. Hence, efforts from health authorities to restrict use are highly
appreciated as these are not well scientifically studied. Despite the popularity of herbal
medicine in Sudan, no clinical studies or randomized clinical trials have yet assessed
the use of these herbal medicines.
4. Conclusion
The world is in a race to find effective treatment and vaccine against COVID-19. This will
continue to be challenging disease, as we have not yet developed a full understanding
of the pathogenesis of COVID-19. Summary of possible potential therapy of COVID-19
was provided in table 1. Drug discovery and clinical trials will need time, and many
peoples may suffer or die as a result of this long wait. The discovery of vaccine or
pharmacological therapy against COVID-19 will be the main success in getting out of
the lockdown of COVID-19.
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